Shows
OncotargetOncotarget to Participate at the AACR Annual Meeting 2025BUFFALO, NY - March 17, 2025 – Impact Journals (Oncotarget’s publisher), is pleased to announce its participation as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2025. The meeting is scheduled for April 25-30, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
The 2025 AACR Annual Meeting's central theme, "Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact," highlights major breakthroughs and innovative developments transforming cancer research. Oncotarget aligns directly with this vision, being always committed to rapidly publishing and disseminating impactful research findings across diverse areas of cancer science and thus advancing cancer treatment and patient care...2025-03-1202 min
OncotargetOncotarget Welcomes New Editorial Board MembersBUFFALO, NY - July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial Board, including our new Co-Editor-in-Chief, Dr. Wafik S. El-Deiry.
Joining Dr. El-Deiry on Oncotarget’s Editorial Board are Dr. Trever Bivona, Dr. Phillip Buckhaults, Dr. Fred Bunz, Dr. Jonathan Chernoff, Dr. Stephen G. Chun, Dr. Nathan Dolloff, Dr. Peiwen Fei, Dr. Justin D. Lathia, Dr. Bora Lim, Dr. Jia (Jenny) Liu, Dr. Hui-Wen Lo, Dr. Emil Lou, Dr. Anirban Maitra, Dr. Ruben A. Mesa, and Dr. Yashbir Singh.
To learn more about our outstanding members, please visit our Editorial Board page.
In celebration of the new additions to O...2024-07-2201 minOncotargetOncotarget Sponsors 19th International p53 Workshop in ItalyBUFFALO, NY- April 29, 2024 – Oncotarget is a contributing #sponsor at the 19th International p53 Workshop, organized by the International Center for Genetic Engineering and Biotechnology (ICGEB), which takes place from May 13–16, 2024, in Trieste, Italy.
“Groundbreaking research and cutting-edge advancements in the field of the most studied human gene and most frequently mutated gene in cancer, will take center stage at the 19th International p53 Workshop.” – ICGEB.org
Among the 24 invited speakers at the 19th International p53 Workshop, 18 speakers have published new research on p53 in Oncotarget. These distinguished speakers who have published with Oncotarget include Dr. Andrei Gudkov — one of Oncotarget’s founding Edi...2024-04-2902 min
OncotargetOncotarget’s Top 10 Papers Published in 2023 (Crossref Data)Crossref is a non-profit organization that logs and updates citations for scientific publications. Each month, Crossref identifies a list of the most popular Oncotarget papers based on the number of times a DOI is successfully resolved.
Below are Crossref’s Top 10 Oncotarget DOIs published in 2023.
10: Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)
DOI: https://doi.org/10.18632/oncotarget.28355
Authors: Md Maksudul Alam, Janmaris Marin Fermin, Mark Knackstedt, Mackenzie J. Noonan, Taylor Powell, Landon Goodreau, Emily K. Daniel, Xiaohua Rong, Tara Moore-Medlin, Alok R. Khandelwal, and Cherie-Ann O. Nat...2024-02-1505 min
OncotargetOncotarget Sponsors 2023 Ride for RoswellThe Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 27 years to celebrate cancer survivors, pay tribute to lives that have been lost, and to work together to support research and find a cure.
When its doors opened in Buffalo in 1898, Roswell Park Comprehensive Cancer Center was the first cancer research-focused institution in the world. Today, this institution is one of only four National Cancer...2023-06-1905 minOncotargetOncotarget at AACR Annual Meeting 2023Impact Journals (Oncotarget's publisher) will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 from April 14-19 at the Orange County Convention Center in Orlando, Florida. This year, the AACR meeting theme is: “Advancing the Frontiers of Cancer Science and Medicine.”
Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals. Oncotarget is indexed/archived on MEDLINE, PMC and PubMed.
Visit booth No. 2642 at the AACR Annual Meeting 2023 to connect with members of t...2023-04-0701 min
OncotargetOncotarget’s Top 10 Papers In 2022 (Crossref Data)Crossref is a non-profit organization that logs and updates citations for scientific publications. Each month, Crossref identifies a list of the most popular Oncotarget papers based on the number of times a DOI is successfully resolved. Below are Crossref’s Top 10 Oncotarget DOIs in 2022.
10: Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects
DOI: https://doi.org/10.18632/oncotarget.28088
Author: Yuri Lazebnik
9: A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies
DOI: https://doi.org/10.18632/oncotarget.24807
Authors: Sandra Rosskopf, Judith Leitner, Wolfgang Paster, Laura T. Morton, Renate S...2023-02-2108 min
OncotargetOncotarget’s Top-10 Most-Viewed Papers in 2021Listen to a list of the 10 most-viewed oncology-focussed papers on Oncotarget.com in 2021.
10 - “Metformin and berberine, two versatile drugs in treatment of common metabolic diseases”
DOI - https://doi.org/10.18632/oncotarget.20807
9 - “Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects”
https://doi.org/10.18632/oncotarget.28088
8 - “Physical activity and telomere length: Impact of aging and potential mechanisms of action”
https://doi.org/10.18632/oncotarget.16726
7 - “Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer”
https://doi.org/10.18632/oncotarget.26473
6 - “cGAS-STING pathway in oncogenesis and cancer therapeutics”
https://doi.org/10.18632/oncotarget.27673
5 - “Anti-aging: senolytic...2022-01-2107 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #16Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 16.
https://www.oncotarget.com/archive/v12/i16/
Cover Paper - “Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma”
https://doi.org/10.18632/oncotarget.28032
Research Paper - “High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer” https://doi.org/10.18632/oncotarget.28029
Research Paper - “MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways”
https://doi.org/10.18632/oncotarget.28030
Review - “Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions” https...2021-08-0406 min
OncotargetOncotarget: Biomarker Predicts Treatment Efficacy in Triple-Negative Breast CancerBiomarkers are any measurement in the body that can indicate disease, infection, or effects of the environment. These indicators are commonly used to reveal disease, but they can also be used to support personalized cancer therapy.
“In recent years, there has been an increased focus on personalized cancer therapy. One important aspect is the identification of key biomarkers that support a given treatment plan.”
Multiple biomarkers have been identified in breast cancers as helpful tools to guide targeted therapies, including the expression of HER2 and estrogen and progesterone receptors. In triple-negative breast cancer (TNBC), a number of distinct biomarkers have given ri...2021-07-2805 min
OncotargetOncotarget: LAPAS1 is required for S phase progression and cell proliferationOncotarget published "A novel E2F1-regulated lncRNA, LAPAS1, is required for S phase progression and cell proliferation" which reported that long non-coding RNAs are major regulators of many cellular processes, including cell cycle progression and cell proliferation.
Inhibition of LAPAS1 expression increases the percentage of S phase cells, and its silencing in synchronized cells delays their progression through S phase.
In agreement with its suggested role in cell cycle progression, prolonged inhibition of LAPAS1 attenuates proliferation of human cancer cells.
Importantly, knockdown of SPNS2 rescues the effect of LAPAS1 silencing on cell cycle and cell proliferation.
Summarily, they identify...2021-07-2602 min
OncotargetOncotarget: Metal Compounds Induce DNA Instability In Cancer CellsOncotarget’s cover paper this week (Volume 12, Issue 15) is entitled, "Terpyridine platinum compounds induce telomere dysfunction and chromosome instability in cancer cells."
About the Study:
Researchers from the National Institutes of Health, University Paris-Saclay, Kazusa DNA Research Institute, and the University of Edinburgh used a dual-Human Artificial Chromosome (HAC) assay to analyze the genomic activity of six telomere-targeting platinum compounds.
The dual-HAC assay was previously created by the researchers in this study to detect compounds that induce CIN through telomere dysfunction. This assay consists of two cell lines: one with telomeres, and one without. Disruption of the cell lines with te...2021-07-2205 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #15Listen to summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 15.
https://www.oncotarget.com/archive/v12/i15/
Cover Paper - “Terpyridine platinum compounds induce telomere dysfunction and chromosome instability in cancer cells”
https://doi.org/10.18632/oncotarget.28020
Research Paper - “RNA expression differences in prostate tumors and tumor-adjacent stroma between Black and White Americans” https://doi.org/10.18632/oncotarget.28024
Research Paper - “Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis”
https://doi.org/10.18632/oncotarget.28011
Research Paper...2021-07-2108 min
OncotargetOncotarget: Targeted Treatment for Recurrent Ovarian CancerOncotarget published this trending research paper on May 1, 2018, entitled, "Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau" by researchers from the Massachusetts General Hospital, Boston, MA; Siamab Therapeutics, Inc., Newton, MA; Harvard Medical School, Boston, MA.
Abstract:
Recurrent ovarian cancer (OvCa) is thought to result in part from the inability to eliminate rare quiescent cancer stem cells (CSCs) that survive cytotoxic chemotherapy and drive tumor resurgence. The Sialyl-Thomsen-nouveau antigen (STn) is a carbohydrate moiety present on protein markers of CSCs in pancreatic, colon, and gastric malignancies. We have demonstrated that human OvCa cell lines contain...2021-07-1605 min
OncotargetOncotarget: Expanding Research With TrendMDOncotarget has started a new venture to expand our reach and connect with other relevant platforms using TrendMD. The TrendMD widget has been applied at the bottom of all research papers on Oncotarget.com to serve recommended content to our readers, and readers on thousands of other high-traffic websites and scholarly platforms. Recommended content is based on the content currently being viewed, content that has been viewed in the past, and content other similar readers are viewing.
“[TrendMD’s] recommendation algorithms continuously optimize the placements of links to your content for the right audience while readers are actively looking for some...2021-07-1503 min
OncotargetOncotarget: Esomeprazole and Tumor ControlThis week's cover paper of Oncotarget (Volume 12, Issue 14) is entitled, "Esomeprazole enhances the effect of ionizing radiation to improve tumor control," by researchers from Baylor College of Medicine, University of Texas MD Anderson Cancer Center, and Texas Children’s Hospital.
Abstract:
The resistance of cancer cells to radiation-based treatment is a major clinical challenge confounding standard of care in cancer. This problem is particularly notable in many solid tumors where cancer cells are only partially responsive to radiation therapy. Combination of radiation with radiosensitizers is able to enhance tumor cell killing. However, currently available radiosensitizers are associated with significant normal ti...2021-07-0804 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #14Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 14.
https://www.oncotarget.com/archive/v12/i14/
Cover Paper - “Esomeprazole enhances the effect of ionizing radiation to improve tumor control” https://doi.org/10.18632/oncotarget.28008
Research Paper - “Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer”
https://doi.org/10.18632/oncotarget.28014
Research Paper - “MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer” https://doi.org/10.18632/oncotarget.28002
Research Paper - “The use of a uPAR-targeted pr...2021-07-0708 min
OncotargetOncotarget: ONC201 Induces Apoptosis in Breast CancerOncotarget published this trending research paper on October 20, 2020, entitled, "TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic" by researchers from Temple University, Philadelphia, PA; Fox Chase Cancer Center, Philadelphia, PA; Brown University, Providence, RI; Brown University and the Lifespan Health System, Providence, RI.
Abstract:
ONC201 was initially identified as an inducer of cell death through the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway. The compound is currently being tested in patients with hematological malignancies and solid tumors, including those of the breast. We investigated strategies to convert the response of breast cancers...2021-07-0206 min
OncotargetOncotarget: LAT1 - A Promising Anti-Cancer TargetThis week's cover paper of Oncotarget (Volume 12, Issue 13) is entitled, "Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target," by researchers from Kindai University, Higashiosaka-Shi, Osaka, Japan; Tohoku University, Sendai-Shi, Miyagi, Japan; Tokyo University of Science, Noda-shi, Chiba, Japan; Hyogo University of Health Sciences, Kobe-Shi, Hyogo, Japan.
Abstract:
L-type amino acid transporter 1 (LAT1)/SLC7A5 is the first identified CD98 light chain disulfide linked to the CD98 heavy chain (CD98hc/SLC3A2). LAT1 transports large neutral amino acids, including leucine, which activates mTOR, and is highly expressed in human cancers...2021-06-2505 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #13Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 13.
https://www.oncotarget.com/archive/v12/i13/
Cover Paper
“Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target”
https://doi.org/10.18632/oncotarget.27981
News
“A new class of radiosensitizers for glioblastoma”
https://doi.org/10.18632/oncotarget.27970 (PDF Download)
Research Paper
“A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection”
https://doi.org/10.18632/oncotarget.27982
Research Paper
“Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous ce...2021-06-2309 min
OncotargetOncotarget: CRISPR Used in Triple Negative Breast Cancer ResearchIn this week's cover paper of Oncotarget (Volume 12, Issue 12), entitled, "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity," researchers used the CRISPR-Cas9 tool to analyze a p53 mutation in triple-negative breast cancer.
The researchers from the City University of New York, Columbia University, and Weill Cornell Medical College wrote that both the C-terminal domain (CTD) and oligomerization domain (OD) of mtp53 R273H proteins are intact, and it is not clear if these regions are responsible for chromatin-based DNA replication activities. To examine the ability...2021-06-1007 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #12Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 12.
The full issue of Oncotarget: https://www.oncotarget.com/archive/v12/i12/
COVER PAPER:
“Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity”
https://doi.org/10.18632/oncotarget.27975
NEWS:
“LY6 gene family presents a novel class of potential biomarkers associated with overall survival outcome of pancreatic ductal adenocarcinoma”
https://doi.org/10.18632/oncotarget.27968 (PDF Download)
EDITORIAL:
“Neoantigen evolution in head and neck cancer progression: Where do we go from here?”
https://doi.org/10.18632/o...2021-06-0906 min
OncotargetOncotarget: Novel Urine Protein Biomarkers In Bladder CancerOncotarget published this trending research paper on April 13, 2021, entitled, "Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens" conducted by researchers from the University of Houston and UT Southwestern Medical Center.
Bladder cancer is four times more common among men than women, and it is the sixth most common cancer diagnosis in the United States. However, researchers have found that cystoscopy—the primary method physicians use to diagnose patients with bladder cancer—is relatively invasive, expensive, and has the potential to cause urinary tract infections.
“In contrast, urine is a noninvasive and readily available biological fluid that can be use...2021-06-0404 min
OncotargetOncotarget: Blood-Based Biomarker in SCCAIn this week's cover paper of Oncotarget (Volume 12, Issue 11) entitled, "CEA as a blood-based biomarker in anal cancer," researchers from The University of Texas – MD Anderson Cancer Center, Terasaki Foundation of Biomedical Sciences, and Vanderbilt Ingram Cancer Center conducted a retrospective, single-institution study to determine the correlation between carcinoembryonic antigen (CEA) levels (a commonly employed assay for patients with colorectal adenocarcinoma) and biopsy-proven Squamous cell carcinoma of the anal canal (SCCA).
The researchers retrospectively analyzed 219 patients who were treated at The University of Texas – MD Anderson Cancer Center between 2013 and 2020. The team collected demographic data, clinical history, and CEA levels, incl...2021-05-2705 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #11Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 11.
View the complete issue: https://www.oncotarget.com/archive/v12/i11/
COVER PAPER:
“CEA as a blood-based biomarker in anal cancer”
https://doi.org/10.18632/oncotarget.27959
NEWS:
“FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?”
https://doi.org/10.18632/oncotarget.27957 (PDF Download)
EDITORIAL:
“Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response”
https://doi.org/10.18632/oncotarget.27927 (PDF Download)
EDITORIAL:
“Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?” https://doi.org/10.18632/oncotarget.27931 (PDF Download)
RESEARCH...2021-05-2608 min
OncotargetOncotarget Launches Special Collection on Skin CancerSkin cancer is a highly preventable cancer (in non-hereditary cases), due to a major risk factor being prolonged exposure to ultraviolet (UV) radiation. However, skin cancer is the most commonly diagnosed cancer in the United States. By the age of 70, one in five Americans are predicted to be diagnosed with skin cancer.
There are three types of cells that are usually involved in skin cancer: basal cells, squamous cells, and melanocytes (or pigment producing cells). The type of skin cell affected by cancer is what classifies the difference between basal cell carcinoma, squamous cell carcinoma, and melanoma.
Basal cell carcinoma...2021-05-2102 min
OncotargetOncotarget: Inhibitory Effects of Tomivosertib in Acute Myeloid LeukemiaIn the cover paper of this week's issue of Oncotarget (Volume 12, Issue 10), titled, "Inhibitory effects of Tomivosertib in acute myeloid leukemia," researchers based out of Chicago, Illinois, U.S., from Northwestern University’s Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, and Jesse Brown Veterans Affairs Medical Center conducted a new study to assess the efficacy of Tomivosertib to regulate the eIF4E binding protein in AML.
In this study, the researchers purchased Tomivosertib (and Venetoclax) from TargetMol. They cultured AML cell lines, used clonogenic leukemic progenitor assays in methylcellulose, cell viability assays, cell lysis and im...2021-05-1306 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #10Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 10.
View the complete issue: https://www.oncotarget.com/archive/v12/i10/
COVER PAPER:
“Inhibitory effects of Tomivosertib in acute myeloid leukemia” https://doi.org/10.18632/oncotarget.27952
EDITORIAL:
“Raman spectroscopy determination of the mineral characteristics of microcalcifications in breast cancer, a way towards an improved screening approach” https://doi.org/10.18632/oncotarget.27912 (PDF Download)
EDITORIAL:
“Reactive oxygen species in leukemias: maintaining cancer cell proliferation via redox signaling and changing metabolic homeostasis” https://doi.org/10.18632/oncotarget.27913 (PDF Download)
RESEARCH PAPER:
“Genome wide DNA methylation landscape reveals glioblastoma’s influence on epige...2021-05-1106 min
OncotargetOncotarget: Evaluating Role of IGF/CTP Composite Score in Sorafenib TreatmentOncotarget published this trending research paper on April 13, 2021, entitled, “Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib,” by researchers from the University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, and Harvard Medical School.
The majority of circulating insulin–like growth factor (IGF) is synthesized and secreted by the liver, and levels of IGF dramatically decrease in chronic liver disease and HCC. IGF can be a helpful tool to determine the prognosis of patients with advanced HCC while undergoing treatment with sorafenib. Researchers also use the Child...2021-05-0805 min
OncotargetOncotarget: A New Class of Radiosensitizers for GlioblastomaIn the cover paper of this week's issue of Oncotarget (Volume 12, Issue 9), titled, "Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore," researchers conducted a study to create mibefradil analogs as superior radiosensitizers for glioblastomas.
In the current study, based on their previous findings, the researchers from Yale University used structure activity relationship analysis and EJ-DR assays to create, synthesize, and profile a series of 140 mibefradil analogs. Their goal was to develop superior mibefradil analogues, with reduced off-target effects and improved potency.
After successfully reducing the known off-target liabilities of mibefradil, the team selected the...2021-04-2905 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #9Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 9.
View the complete issue: https://www.oncotarget.com/archive/v12/i9/
Oncotarget Volume 12, Issue 9 features:
COVER PAPER:
“Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore” https://doi.org/10.18632/oncotarget.27933
EDITORIAL:
“Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?” https://doi.org/10.18632/oncotarget.27904 (PDF Download)
EDITORIAL:
“Epigenetic effects of pharmacologic ascorbate” https://doi.org/10.18632/oncotarget.27911 (PDF Download)
RESEARCH PAPER:
“Activation of plasmacytoid dendritic cells promotes AML-cell fratricide” https://doi.org/10.18632/oncotarget.27949
RESEARCH PAPER:
“Piperlongumine promotes death of retinoblast...2021-04-2807 min
OncotargetOncotarget: Midostaurin Drug Sensitivity Ex Vivo in Acute Myeloid LeukemiaOncotarget published this trending paper on July 21, 2020, entitled, “Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients,” by researchers from Knight Cancer Institute, Oregon Health and Science University; Division of Hematology and Medical Oncology, Oregon Health and Science University; Howard Hughes Medical Institute; Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University.
The researchers conducted a study to identify features that may predict response to midostaurin in FLT3 mutant and wild-type samples. They performed an ex vivo drug sensitivity screen on primary and relapsed AML samples, with corresponding targeted sequencing and...2021-04-2705 min
OncotargetOncotarget: A New Potential Network of Biomarkers Useful Across SarcomasIn the cover paper of this week's issue of Oncotarget (Volume 12, Issue 8), titled, "Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas," researchers examined five potential biomarkers across 18 different histologic subtypes of sarcoma in 163 tissue samples. Immunohistochemical staining, statistical analysis, and correlation-based network analysis revealed promising results.
Researchers from the University of Iowa, University of Alabama at Birmingham, and the Mayo Clinic, report the need for additional prognostic and therapeutic biomarkers to predict clinical behavior across different histological types of sarcoma.
“Although the French (FNCLCC) and NCI grading schemes have been adopted for ma...2021-04-1508 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #8Listen to short summaries of the latest oncology-focused research published in this week's issue of Oncotarget. https://www.oncotarget.com/archive/v12/i8/
Oncotarget Volume 12, Issue 8 features:
COVER PAPER:
“Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas” https://doi.org/10.18632/oncotarget.27928
NEWS:
“Immunotherapy and fatigue: what we know and what we don’t know” https://doi.org/10.18632/oncotarget.27946 (PDF Download)
EDITORIAL:
“Drug exposure: still relevant after all these years” https://doi.org/10.18632/oncotarget.27899 (PDF Download)
EDITORIAL:
“Up to your NEK2 in CIN” https://doi.org/10.18632/oncotarget.27918 (PDF Download)
RESEARCH PAPER:
“Analytic validation and clinical utiliza...2021-04-1409 min
OncotargetOncotarget: First Blood Test for Early Melanoma Detection (A 2018 Study)In this top-performing paper published in Oncotarget on July 17, 2018, entitled, “A diagnostic autoantibody signature for primary cutaneous melanoma,” Australian researchers developed the first blood test to detect melanoma in early stages.
The researchers from Australia’s Edith Cowan University, Hollywood Private Hospital, Level 1 Melanoma, St. John of God Hospital, Dermatology Specialist Group, Skin Check WA, and The University of Western Australia collected blood sera (plural of serum, which contains exogenous substances in the blood, such as electrolytes, antibodies, autoantibodies, antigens, and hormones) from a total of 245 primary melanoma patients and healthy volunteers. The sera were screened against a high-throughput microarray profil...2021-04-0705 min
OncotargetOncotarget: Caloric Restriction and Aging Delay in Budding YeastIn Oncotarget Volume 12, Issue 7 cover paper, titled, "Caloric restriction creates a metabolic pattern of chronological aging delay that in budding yeast differs from the metabolic design established by two other geroprotectors," the researchers conducted a study which compared the metabolic effects of three geroprotectors in budding yeast: calorie restriction, the tor1Δ mutation, and lithocholic acid.
In this study, the researchers from the Department of Biology at Concordia University in Montreal, Quebec, used chronologically aging Saccharomyces cerevisiae—a common budding yeast found in baking, winemaking, and beer brewing. S. cerevisiae is a fungus useful for measuring the mechanisms of aging. The res...2021-04-0206 min
OncotargetOncotarget: Participating in the AACR Annual MeetingThe American Association for Cancer Research (AACR) organizes an annual meeting program covering some of the most recent discoveries in cancer research. The conference aims to highlight work from the best minds in research and medicine from institutions all over the world. Oncotarget, exhibited by its publisher Impact Journals, will be participating virtually at the AACR Annual Meeting this year.
Visit the Oncotarget website: www.oncotarget.com
Visit the Impact Journals website: www.impactjournals.com
As of June 2020, Scopus released their latest 2019 Journal Rankings on Oncology. Oncotarget is among their highest rated (Q1) journals and ranked number one in total...2021-04-0203 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #7Listen to short summaries of the latest oncology-focused research published in this week's issue of Oncotarget. https://www.oncotarget.com/archive/v12/i7/
Oncotarget Volume 12, Issue 7 features:
COVER PAPER:
"Caloric restriction creates a metabolic pattern of chronological aging delay that in budding yeast differs from the metabolic design established by two other geroprotectors"
https://doi.org/10.18632/oncotarget.27926
EDITORIAL:
"The long road to TRAIL therapy: a TRAILshort detour"
https://doi.org/10.18632/oncotarget.27902
RESEARCH PERSPECTIVE:
"The role of immune surveillance in malignant transformation of benign salivary gland tumors"
https://doi.org/10.18632/oncotarget.27900
RESEARCH PAPER:
"Differential expression of Vitamin D binding protein in...2021-04-0210 min
OncotargetOncotarget: Neoantigen Evolution in Head and Neck TumorsIn the cover paper of this week's issue of Oncotarget, titled: "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma," the aim of the researchers in this exploratory study was to characterize the genomic and neoantigen changes in 23 paired primary and recurrent HNSCC tumors.
Of the 23 patients in this study, 17 were male and 14 were tobacco smokers. The distribution of primary tumor location was nine in the oral cavity, seven in the oropharynx, six in the larynx, and one in the hypopharynx. The researchers note that all seven patients with an oropharyngeal primary...2021-03-1707 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #6Listen to short summaries of the latest oncology-focused research literature published in this week's issue of Oncotarget.
https://www.oncotarget.com/archive/v12/i6/
Oncotarget Volume 12, Issue 6 features:
COVER PAPER:
"Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma."
Institutions: Washington University in St. Louis, Columbia University, St. Louis Children’s Hospital, Siteman Cancer Center
Quote: “We characterized genomic and neoantigen changes between 23 paired primary and recurrent HNSCC tumors. Twenty-three biopsies from patients originally diagnosed with locally advanced disease were identified from the Washington University tumor bank.”
doi.org/10.18632/oncotarget.27907
EDITORIAL:
"Innovating and ex...2021-03-1604 min
OncotargetOncotarget: Hepatocellular Carcinoma in The Andes MountainsIn a trending paper published by Oncotarget on March 2, 2021, researchers conducted a study to better understand why young Andean people are disproportionately affected by hepatocellular carcinoma (HCC) than others around the world.
Hepatocellular carcinoma (HCC) is one of the most heterogeneous forms of cancer, and affects older patients commonly after they have had prolonged liver disease. However, among Andean people, half of the total patients who develop HCC are adolescents and young adults. Researchers—from Sorbonne Université, Institut Pasteur, Université de Rennes, and Université de Toulouse in France, and the Instituto Nacional de Enfermedades Neoplásicas in Peru—conducted a study to...2021-03-1205 min
OncotargetOncotarget: Can Precision Oncology Improve Patient Survival AND Cut Costs?Oncotarget published this top-performing paper in 2018, when researchers compared the overall survival, average total healthcare costs, and resource utilization among patients with advanced cancers who received either standard care or precision, targeted oncology.
The researchers, from Intermountain Healthcare facilities (located in Utah and California, U.S.) and California’s Stanford University School of Medicine, conducted a well-read study published in 2018, titled: “Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs.” This paper currently presents with an Altmetric attention score of 484.
Read about the study: https://www.oncotarget.com/article/24384/text/
Top Oncotarget publications rated by Altmet...2021-03-1005 min
OncotargetOncotarget: The First Study on CABYR Isoforms in Colorectal CancerIn the cover paper of this week's issue of Oncotarget, titled: "The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy," researchers evaluate CABYR isoforms a/b and c mRNA expression in colorectal cancer in hopes of determining whether or not these proteins may be promising vaccine targets.
Read the full study here: https://doi.org/10.18632/oncotarget.27897
Oncotarget Volume 12, Issue 5: https://www.oncotarget.com/archive/v12/i5/
About Oncotarget:
Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To...2021-03-0506 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #5Listen to short summaries of the latest oncology-focused research literature published in this week's issue of Oncotarget Volume 12, Issue 5.
Click here for the complete issue: https://www.oncotarget.com/archive/v12/i5/
Oncotarget Volume 12, Issue 5 features:
Cover Paper: "The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy." https://doi.org/10.18632/oncotarget.27897
Research Perspective: "Tumor mutational burden as a predictor of immunotherapy response in breast cancer." https://doi.org/10.18632/oncotarget.27877
Research Paper: "STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells." https://doi.org/10.18632...2021-03-0308 minOncotargetOncotarget Podcast Episodes: The Latest in Oncology-Focused ResearchHundreds of scientific studies, reviews, and analyses are being published from around the world at any given time. This can make reading the latest research literature a time consuming task—depending, of course, on the quantity of papers one hopes to consume. As a tool to help alleviate this important undertaking, many researchers have taken to listening to one of the top open-access podcasts of 2020 and 2021: The Oncotarget Podcast.
After a paper is published, it is added to an enhanced post-publication service provided by Oncotarget, in an effort to help authors reach a wider audience. This podcast series is another wa...2021-02-2402 min
OncotargetOncotarget Podcast - Characterization Of Porcine Hepatocellular Carcinoma For Liver CancerThe cover for issue 28 of Oncotarget features Figure 5, "TMEM165 expression levels alters N-linked glycosylation," by Murali, et al., and reported that the TMEM165 protein was not detected in non-malignant matched breast tissues and was detected in invasive ductal breast carcinoma tissues by mass spectrometry.
The hypothesis is that the TMEM165 protein confers a growth advantage to breast cancer.
The authors created a CRISPR/Cas9 knockout of TMEM165 in the human invasive breast cancer cell line MDAMB231.
Furthermore, they find that TMEM165 expression alters the glycosylation of breast cancer cells and these changes promote the invasion and growth of breast cancer...2021-01-1105 min
OncotargetOncotarget Podcast - Characterization Of Porcine Hepatocellular Carcinoma For Liver CancerThe cover for issue 28 of Oncotarget features Figure 5, "TMEM165 expression levels alters N-linked glycosylation," by Murali, et al., and reported that the TMEM165 protein was not detected in non-malignant matched breast tissues and was detected in invasive ductal breast carcinoma tissues by mass spectrometry.
The hypothesis is that the TMEM165 protein confers a growth advantage to breast cancer.
The authors created a CRISPR/Cas9 knockout of TMEM165 in the human invasive breast cancer cell line MDAMB231.
Furthermore, they find that TMEM165 expression alters the glycosylation of breast cancer cells and these changes promote the invasion and growth of breast cancer...2021-01-1105 min
OncotargetOncotarget - CART Tree Analysis For Overall Survival In IMDC Intermediate Risk GroupThe cover for issue 49 of Oncotarget features Figure 4, "CART-Tree analysis for overall survival in IMDC intermediate risk group," by Guida, et al.recently published in "Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma" which reported that as these patients have different prognosis, the aim of this study is to better characterize IR patients in order to better tailor the treatment.
A multivariable Cox model with backward selection procedure and a Classification and Regression Tree analysis were performed to identify which prognostic factors were associated to OS in IR...2020-12-1003 min
OncotargetOncotarget - CART Tree Analysis For Overall Survival In IMDC Intermediate Risk GroupThe cover for issue 49 of Oncotarget features Figure 4, "CART-Tree analysis for overall survival in IMDC intermediate risk group," by Guida, et al.recently published in "Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma" which reported that as these patients have different prognosis, the aim of this study is to better characterize IR patients in order to better tailor the treatment.
A multivariable Cox model with backward selection procedure and a Classification and Regression Tree analysis were performed to identify which prognostic factors were associated to OS in IR...2020-12-1003 min
OncotargetOncotarget Podcast: IGF2 expression in breast cancer tumors and in breast cancer cellsThe cover for issue 44 of Oncotarget features Figure 1, "Schematic diagram of the human IGF2 gene structure," by Radhakrishnan, et al. recently published in "Methylation of a newly identified region of the INS-IGF2 gene determines IGF2 expression in breast cancer tumors and in breast cancer cells" which reported that these authors previously demonstrated that IGF2 protein levels are higher in BC tissues from African American women than in Caucasian women.
They also showed that high IGF2 protein levels are expressed in normal breast tissues of African American women while little or no IGF2 was detected in tissues from Caucasian women.
Thus...2020-11-0603 min
OncotargetOncotarget Podcast: IGF2 expression in breast cancer tumors and in breast cancer cellsThe cover for issue 44 of Oncotarget features Figure 1, "Schematic diagram of the human IGF2 gene structure," by Radhakrishnan, et al. recently published in "Methylation of a newly identified region of the INS-IGF2 gene determines IGF2 expression in breast cancer tumors and in breast cancer cells" which reported that these authors previously demonstrated that IGF2 protein levels are higher in BC tissues from African American women than in Caucasian women.
They also showed that high IGF2 protein levels are expressed in normal breast tissues of African American women while little or no IGF2 was detected in tissues from Caucasian women.
Thus...2020-11-0603 min
OncotargetOncotarget - Exosomes Secreted Under Hypoxia Enhance Stemness In Ewing's SarcomaThe cover for issue 40 of Oncotarget features Figure 5, "miR-210 silences the proapoptosis member CASP8AP2," by Kling, et al. which reported that hypoxic Ewing's sarcoma cells release exosomes that promote sphere formation, a stem-like phenotype, in EWS cells by enhancing survival.
Analysis of the hypoxic exosomal miRNA cargo identified a HIF-1α regulated miRNA, miR-210, as a potential mediator of sphere formation in cells exposed to hypoxic exosomes.
The knockdown of HIF-1α in hypoxic EWS cells led to decreased exosomal miR-210 levels and reduced the capacity of hypoxic exosomes to form spheres.
Inhibition of miR-210 in hypoxic spheres attenuated sphere formation an...2020-10-0804 min
OncotargetOncotarget - Exosomes Secreted Under Hypoxia Enhance Stemness In Ewing's SarcomaThe cover for issue 40 of Oncotarget features Figure 5, "miR-210 silences the proapoptosis member CASP8AP2," by Kling, et al. which reported that hypoxic Ewing's sarcoma cells release exosomes that promote sphere formation, a stem-like phenotype, in EWS cells by enhancing survival.
Analysis of the hypoxic exosomal miRNA cargo identified a HIF-1α regulated miRNA, miR-210, as a potential mediator of sphere formation in cells exposed to hypoxic exosomes.
The knockdown of HIF-1α in hypoxic EWS cells led to decreased exosomal miR-210 levels and reduced the capacity of hypoxic exosomes to form spheres.
Inhibition of miR-210 in hypoxic spheres attenuated sphere formation an...2020-10-0804 min
OncotargetOncotarget - NRXN1 As A Novel Potential Target For Small Cell Lung CancerThe cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.
The cell surface overexpression of NRXN1 was confirmed using flow cytometry in SCLC cell lines.
The combination of a primary anti-NRXN1 monoclonal antibody and a secondary ADC exhibited anti-tumor activity in SCLC cell lines.
Moreover, the knockout of NRXN1 in SHP77 cells resulted in...2020-09-3003 min
OncotargetOncotarget - NRXN1 As A Novel Potential Target For Small Cell Lung CancerThe cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.
The cell surface overexpression of NRXN1 was confirmed using flow cytometry in SCLC cell lines.
The combination of a primary anti-NRXN1 monoclonal antibody and a secondary ADC exhibited anti-tumor activity in SCLC cell lines.
Moreover, the knockout of NRXN1 in SHP77 cells resulted in...2020-09-3003 min
OncotargetOncotarget - A Comprehensive Analysis Of Clinical Trials In Pancreatic CancerThe cover for issue 38 of Oncotarget features Figure 3, "Summary of the time and cost for drug development (modified from DiMasi et al [2016]," by Katayama, et al. which reported that Pancreatic cancer is the most aggressive common cancer and is desperately in need of novel therapies.
In this study, the Oncotarget authors perform the first comprehensive analysis of the current clinical trial landscape in pancreatic cancer to better understand the pipeline of new therapies.
Studies were curated and categorized according to the phase of the study, the clinical stage of the study population, type of intervention under investigation, and biologic mechanism...2020-09-2303 min
OncotargetOncotarget - A Comprehensive Analysis Of Clinical Trials In Pancreatic CancerThe cover for issue 38 of Oncotarget features Figure 3, "Summary of the time and cost for drug development (modified from DiMasi et al [2016]," by Katayama, et al. which reported that Pancreatic cancer is the most aggressive common cancer and is desperately in need of novel therapies.
In this study, the Oncotarget authors perform the first comprehensive analysis of the current clinical trial landscape in pancreatic cancer to better understand the pipeline of new therapies.
Studies were curated and categorized according to the phase of the study, the clinical stage of the study population, type of intervention under investigation, and biologic mechanism...2020-09-2303 min
OncotargetOncotarget - Sirolimus - Eluting Stents - Opposite In Vitro Effects On The Clonogenic Cell PotentialThe cover for issue 31 of Oncotarget features Figure 4, "Concentration dose-response curves of sirolimus effect [55 nM–1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure," by Vasuri, et al. which reported that the authors evaluated the long-term effects of sirolimus on three different cell in vitro models, cultured in physiological conditions mimicking sirolimus-eluted stent, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival.
Three cell lines were selected and growth in 10 ml of Minimum Essential Medium for 5 weeks with serial dilutions of sirolimus.
The number of colonies and th...2020-08-0503 min
OncotargetOncotarget - Sirolimus - Eluting Stents - Opposite In Vitro Effects On The Clonogenic Cell PotentialThe cover for issue 31 of Oncotarget features Figure 4, "Concentration dose-response curves of sirolimus effect [55 nM–1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure," by Vasuri, et al. which reported that the authors evaluated the long-term effects of sirolimus on three different cell in vitro models, cultured in physiological conditions mimicking sirolimus-eluted stent, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival.
Three cell lines were selected and growth in 10 ml of Minimum Essential Medium for 5 weeks with serial dilutions of sirolimus.
The number of colonies and th...2020-08-0503 min
OncotargetOncotarget: Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2)The cover for issue 29 of Oncotarget features Figure 5, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling. In the present study, the authors examined the biological effects of liposomal antisense oligodeoxynucleotide that blocks Grb2 expression in gynecologic cancer models.
Murine orthotopic models of ovarian and uterine cancer were used to study the biological effects of L-Grb2 on tumor growth.
In vitro experiments were carried out to elucidate the mechanisms and...2020-07-2203 min
OncotargetOncotarget: Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2)The cover for issue 29 of Oncotarget features Figure 5, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling. In the present study, the authors examined the biological effects of liposomal antisense oligodeoxynucleotide that blocks Grb2 expression in gynecologic cancer models.
Murine orthotopic models of ovarian and uterine cancer were used to study the biological effects of L-Grb2 on tumor growth.
In vitro experiments were carried out to elucidate the mechanisms and...2020-07-2203 minOncotargetOncotarget - Exploring The Role Of Survivin In Neuroendocrine NeoplasmsOncotarget - Exploring The Role Of Survivin In Neuroendocrine Neoplasms by Oncotarget Podcast2020-07-1504 min
OncotargetOncotarget - Exploring The Role Of Survivin In Neuroendocrine NeoplasmsOncotarget - Exploring The Role Of Survivin In Neuroendocrine Neoplasms by Oncotarget Podcast2020-07-1504 minOncotargetOncotarget - The Role Of EGFR Mutations In Predicting Recurrence In Lung AdenocarcinomaOncotarget - The Role Of EGFR Mutations In Predicting Recurrence In Lung Adenocarcinoma by Oncotarget Podcast2020-07-1503 min
OncotargetOncotarget - The Role Of EGFR Mutations In Predicting Recurrence In Lung AdenocarcinomaOncotarget - The Role Of EGFR Mutations In Predicting Recurrence In Lung Adenocarcinoma by Oncotarget Podcast2020-07-1503 minOncotargetOncotarget - Adoptive Cell Therapy In Combination With Checkpoint InhibitorsOncotarget - Adoptive Cell Therapy In Combination With Checkpoint Inhibitors by Oncotarget Podcast2020-07-1503 min
OncotargetOncotarget - Adoptive Cell Therapy In Combination With Checkpoint InhibitorsOncotarget - Adoptive Cell Therapy In Combination With Checkpoint Inhibitors by Oncotarget Podcast2020-07-1503 minOncotargetOncotarget - Hyperprogression To Immune Blockade Followed By A Response With CabozantinibOncotarget - Hyperprogression To Immune Blockade Followed By A Response With Cabozantinib by Oncotarget Podcast2020-07-1503 min
OncotargetOncotarget - Hyperprogression To Immune Blockade Followed By A Response With CabozantinibOncotarget - Hyperprogression To Immune Blockade Followed By A Response With Cabozantinib by Oncotarget Podcast2020-07-1503 min
OncotargetOncotarget - Tumor Markers For Carcinoma Identified By Imaging Mass SpectrometryVolume 11, Issue 28 of Oncotarget features "Lipid and protein tumor markers for head and neck squamous cell carcinoma identified by imaging mass spectrometry" by Schmidt et, al. which reported that the authors used MALDI imaging mass spectrometry and immunohistochemistry to seek tumor-specific expression of proteins and lipids in HNSCC samples.
DOI - https://doi.org/10.18632/oncotarget.27649
Full text - https://www.oncotarget.com/article/27649/text/
Correspondence to - Zsolt Balogi - zsolt.balogi@aok.pte.hu and László Márk - laszlo.mark@aok.pte.hu
Keywords - Imaging mass spectrometry, tumor marker, lipid tumor marker, S100A8, S100A9
Abo...2020-07-1304 min
OncotargetOncotarget - Tumor Markers For Carcinoma Identified By Imaging Mass SpectrometryVolume 11, Issue 28 of Oncotarget features "Lipid and protein tumor markers for head and neck squamous cell carcinoma identified by imaging mass spectrometry" by Schmidt et, al. which reported that the authors used MALDI imaging mass spectrometry and immunohistochemistry to seek tumor-specific expression of proteins and lipids in HNSCC samples.
DOI - https://doi.org/10.18632/oncotarget.27649
Full text - https://www.oncotarget.com/article/27649/text/
Correspondence to - Zsolt Balogi - zsolt.balogi@aok.pte.hu and László Márk - laszlo.mark@aok.pte.hu
Keywords - Imaging mass spectrometry, tumor marker, lipid tumor marker, S100A8, S100A9
Abo...2020-07-1304 min
OncotargetOncotarget: miR-708-5p targets oncogenic prostaglandin E2 production in lung cancer cellVolume 11, Issue 26 of Oncotarget reported that Lung cancer is of particular importance, as it is the deadliest cancer worldwide.
In this study, the authors show that high mi R-708 expression is associated with survival rates in lung squamous cell carcinoma patients. mi R-708 also represses PGE2 production by suppressing both COX-2 and mPGES-1 expression in lung cancer cells.
Moreover, mi R-708 decreases proliferation, survival, and migration of lung cancer cells, which can be partially attributed to mi R-708's inhibition of PGE2 signaling.
Lastly, they identify novel mi R-708 predicted targets and possible regulators of mi R-708 expression in lung...2020-07-0703 min
OncotargetOncotarget: miR-708-5p targets oncogenic prostaglandin E2 production in lung cancer cellVolume 11, Issue 26 of Oncotarget reported that Lung cancer is of particular importance, as it is the deadliest cancer worldwide.
In this study, the authors show that high mi R-708 expression is associated with survival rates in lung squamous cell carcinoma patients. mi R-708 also represses PGE2 production by suppressing both COX-2 and mPGES-1 expression in lung cancer cells.
Moreover, mi R-708 decreases proliferation, survival, and migration of lung cancer cells, which can be partially attributed to mi R-708's inhibition of PGE2 signaling.
Lastly, they identify novel mi R-708 predicted targets and possible regulators of mi R-708 expression in lung...2020-07-0703 min
OncotargetOncotarget Podcast - A 3D Biofabricated Cutaneous Squamous Cell Carcinoma Tissue ModelThe cover for issue 27 of Oncotarget features Figure 4, "(A) Bimodal imaging examples of control and treated tumors (red) before and after the treatment period," by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.
Fluorescence-derived imaging biomarkers indicated that 50% of cancer cells were killed in the tissue after 1μM 5-Fluorouracil 48-hour treatment, compared to a baseline of 12% for untreated controls.
The imaging biomarkers also showed that normal keratinocytes were less affected by treatment than the untreated tissue, w...2020-07-0403 min
OncotargetOncotarget Podcast: Clonality and antigen-specific responses shape prognostic effectsOncotarget Volume 11, Issue 27 published "Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer" by Tsuji et al. which reported that to delineate the complexity of anti-tumor T-cell responses, the author's utilized a computational method for de novo assembly of sequences from CDR3 regions of 369 high-grade serous ovarian cancers from TCGA, and then applied deep TCR-sequencing for analyses of paired tumor and peripheral blood specimens from an independent cohort of 99 ovarian cancer patients.
In the validation cohort, the authors' discovered that patients with low T-cell infiltration but low diversity or focused repertoires had clinical outcomes...2020-07-0404 min
OncotargetOncotarget Podcast - A 3D Biofabricated Cutaneous Squamous Cell Carcinoma Tissue ModelThe cover for issue 27 of Oncotarget features Figure 4, "(A) Bimodal imaging examples of control and treated tumors (red) before and after the treatment period," by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.
Fluorescence-derived imaging biomarkers indicated that 50% of cancer cells were killed in the tissue after 1μM 5-Fluorouracil 48-hour treatment, compared to a baseline of 12% for untreated controls.
The imaging biomarkers also showed that normal keratinocytes were less affected by treatment than the untreated tissue, w...2020-07-0403 min
OncotargetOncotarget Podcast: Epigenetic feedback and stochastic partitioning can drive resistance to EMTOncotarget Volume 11, Issue 27 reported that Epithelial-mesenchymal transition (EMT) and its reverse process mesenchymal-epithelial transition are central to metastatic aggressiveness and therapy resistance in solid tumors.
While molecular determinants of both processes have been extensively characterized, the heterogeneity in the response of tumor cells to EMT and MET inducers has come into focus recently and has been implicated in the failure of anti-cancer therapies.
Recent experimental studies have shown that some cells can undergo an irreversible EMT depending on the duration of exposure to EMT-inducing signals.
While the irreversibility of MET, or equivalently, resistance to EMT, has not been studied in...2020-07-0405 min
OncotargetOncotarget Podcast - Correction Of NSE Concentration Improves Diagnostic Accuracy In Lung CancerOncotarget Volume 11, Issue 27 published "Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer" by Genet et al. which reported that this study aimed to develop a hemolysis correction equation and evaluate its role in small-cell lung cancer (SCLC) diagnostics.
A hemolysis correction equation was obtained by analyzing the relationship between the measured Neuron-specific enolase (NSE) concentration and the degree of hemolysis.
Correction of the measured NSE concentration in patients suspected of lung cancer caused an increase in AUC and a significantly lower cut-off value for SCLC detection when compared to uncorrected results.
...2020-07-0403 min
OncotargetOncotarget Podcast: Clonality and antigen-specific responses shape prognostic effectsOncotarget Volume 11, Issue 27 published "Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer" by Tsuji et al. which reported that to delineate the complexity of anti-tumor T-cell responses, the author's utilized a computational method for de novo assembly of sequences from CDR3 regions of 369 high-grade serous ovarian cancers from TCGA, and then applied deep TCR-sequencing for analyses of paired tumor and peripheral blood specimens from an independent cohort of 99 ovarian cancer patients.
In the validation cohort, the authors' discovered that patients with low T-cell infiltration but low diversity or focused repertoires had clinical outcomes...2020-07-0404 min
OncotargetOncotarget Podcast - Correction Of NSE Concentration Improves Diagnostic Accuracy In Lung CancerOncotarget Volume 11, Issue 27 published "Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer" by Genet et al. which reported that this study aimed to develop a hemolysis correction equation and evaluate its role in small-cell lung cancer (SCLC) diagnostics.
A hemolysis correction equation was obtained by analyzing the relationship between the measured Neuron-specific enolase (NSE) concentration and the degree of hemolysis.
Correction of the measured NSE concentration in patients suspected of lung cancer caused an increase in AUC and a significantly lower cut-off value for SCLC detection when compared to uncorrected results.
...2020-07-0403 min
OncotargetOncotarget Podcast: Epigenetic feedback and stochastic partitioning can drive resistance to EMTOncotarget Volume 11, Issue 27 reported that Epithelial-mesenchymal transition (EMT) and its reverse process mesenchymal-epithelial transition are central to metastatic aggressiveness and therapy resistance in solid tumors.
While molecular determinants of both processes have been extensively characterized, the heterogeneity in the response of tumor cells to EMT and MET inducers has come into focus recently and has been implicated in the failure of anti-cancer therapies.
Recent experimental studies have shown that some cells can undergo an irreversible EMT depending on the duration of exposure to EMT-inducing signals.
While the irreversibility of MET, or equivalently, resistance to EMT, has not been studied in...2020-07-0405 min
OncotargetOncotarget Podcast - Australian Experience Of Peptide Receptor Radionuclide TherapyOncotarget Volume 11, Issue 27 published "Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours" by Lim et al. which reported peptide receptor radionuclide therapy (PRRT) is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours, although Phase III randomised clinical trial data is not available for NETs of other site of origin, in practice, PRRT is used more widely in clinical practice, based on its mechanism of targeting the somatostatin receptor.
A retrospective chart review of patients with TC and AC who received 177Lu-dotatate PRRT between January 2002 and June 2019 in six hospitals across Australia was undertaken.
Forty-eight patients received a...2020-07-0203 min
OncotargetOncotarget Podcast - Australian Experience Of Peptide Receptor Radionuclide TherapyOncotarget Volume 11, Issue 27 published "Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours" by Lim et al. which reported peptide receptor radionuclide therapy (PRRT) is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours, although Phase III randomised clinical trial data is not available for NETs of other site of origin, in practice, PRRT is used more widely in clinical practice, based on its mechanism of targeting the somatostatin receptor.
A retrospective chart review of patients with TC and AC who received 177Lu-dotatate PRRT between January 2002 and June 2019 in six hospitals across Australia was undertaken.
Forty-eight patients received a...2020-07-0203 min
OncotargetOncotarget Podcast - The Role Of MiRNA - 133b And Its Target Gene SIRT1 In FAPVolume 11, Issue 26 of Oncotarget reported that in this study the authors studied the differences in mi RNA expression between sporadic and FAP-associated Desmoid tumors using microarray confirmed by quantitative PCR.
Among them, mi R-133b levels were significantly lower in FAP-associated Desmoid tumors than in sporadic Desmoid tumors. The qPCR analysis showed that SIRT1 mRNA levels were significantly up-regulated in FAP-associated Desmoid tumor than in sporadic Desmoid tumor, whereas no differences in ELAVL1 expression was observed between these two Desmoid tumor types.
In addition, a negative correlation was observed between mi R-133b and SIRT1 in FAP-associated Desmoid tumors, but...2020-06-3004 min
OncotargetOncotarget Podcast - The Role Of MiRNA - 133b And Its Target Gene SIRT1 In FAPVolume 11, Issue 26 of Oncotarget reported that in this study the authors studied the differences in mi RNA expression between sporadic and FAP-associated Desmoid tumors using microarray confirmed by quantitative PCR.
Among them, mi R-133b levels were significantly lower in FAP-associated Desmoid tumors than in sporadic Desmoid tumors. The qPCR analysis showed that SIRT1 mRNA levels were significantly up-regulated in FAP-associated Desmoid tumor than in sporadic Desmoid tumor, whereas no differences in ELAVL1 expression was observed between these two Desmoid tumor types.
In addition, a negative correlation was observed between mi R-133b and SIRT1 in FAP-associated Desmoid tumors, but...2020-06-3004 min
OncotargetOncotarget Podcast - IQGAP1 Control Of Centrosome Function Defines Variants Of Breast CancerOncotarget: IQGAP1 control of centrosome function defines variants of breast cancer
The cover for issue 26 of Oncotarget features Figure 6, "Mislocalization of IQGAP1-BRCA1 in human TNBC tumors phenocopies the dominant mutants and the TNBC cells," by Osman, et al. and reported that IQGAP1 is a signaling scaffold implicated in TNBC, but its mechanism is unknown.
Genetic mutant analyses suggest that phosphorylation cycling of IQGAP1 is important to its subcellular localization and centrosome-nuclear shuttling of BRCA1; dysfunction of this process defines two alternate mechanisms associated with cell proliferation.
TNBC cell lines and patient tumor tissues differentially phenocopy these mechanisms supporting the...2020-06-3004 min
OncotargetOncotarget Podcast - IQGAP1 Control Of Centrosome Function Defines Variants Of Breast CancerOncotarget: IQGAP1 control of centrosome function defines variants of breast cancer
The cover for issue 26 of Oncotarget features Figure 6, "Mislocalization of IQGAP1-BRCA1 in human TNBC tumors phenocopies the dominant mutants and the TNBC cells," by Osman, et al. and reported that IQGAP1 is a signaling scaffold implicated in TNBC, but its mechanism is unknown.
Genetic mutant analyses suggest that phosphorylation cycling of IQGAP1 is important to its subcellular localization and centrosome-nuclear shuttling of BRCA1; dysfunction of this process defines two alternate mechanisms associated with cell proliferation.
TNBC cell lines and patient tumor tissues differentially phenocopy these mechanisms supporting the...2020-06-3004 min
OncotargetOncotarget - Tumor Suppressor P53 Regulates Insulin Receptor Gene ExpressionVolume 11, Issue 25 of @Oncotarget reported that the present study was aimed at evaluating the hypothesis that p53 governs the expression and activation of the INSR gene in breast cancer cells.
The availability of MCF7 breast cancer-derived cell lines with specific disruption of either the insulin-like growth factor-1 receptor or INSR allowed us to address the impact of the IGF1R and INSR pathways on p53 expression.
Wild-type p53 stimulated INSR promoter activity in control cells while disruption of endogenous IGF1R or INSR led to inhibition of promoter activity by p53.
Mutant p53 strongly stimulated INSR promoter.
Furthermore, p53 directly...2020-06-2304 min
OncotargetOncotarget - RSK Inhibitor BI - D1870 Inhibits Acute Myeloid Leukemia Cell ProlferationVolume 11, Issue 25 of @Oncotarget reported that to examine the role of RSK in AML, the authors analyzed apoptosis and the cell cycle profile following treatment with BI-D1870, a potent inhibitor of RSK. BI-D1870 treatment increased the G2/M population and induced apoptosis in Acute Myeloid Leukemia cell lines and patient Acute Myeloid Leukemia cells.
Therefore, the authors investigated whether BI-D1870 potentiates the anti-leukemic activity of vincristine by targeting mitotic exit.
Combination treatment of BI-D1870 and vincristine synergistically increased mitotic arrest and apoptosis in acute leukemia cells.
These data show that BI-D1870 induces apoptosis of AML cells alone and in combination...2020-06-2304 min
OncotargetOncotarget - Tumor Suppressor P53 Regulates Insulin Receptor Gene ExpressionVolume 11, Issue 25 of @Oncotarget reported that the present study was aimed at evaluating the hypothesis that p53 governs the expression and activation of the INSR gene in breast cancer cells.
The availability of MCF7 breast cancer-derived cell lines with specific disruption of either the insulin-like growth factor-1 receptor or INSR allowed us to address the impact of the IGF1R and INSR pathways on p53 expression.
Wild-type p53 stimulated INSR promoter activity in control cells while disruption of endogenous IGF1R or INSR led to inhibition of promoter activity by p53.
Mutant p53 strongly stimulated INSR promoter.
Furthermore, p53 directly...2020-06-2304 min
OncotargetOncotarget - Mutation Profile Of Primary Subungual Melanomas In CaucasiansVolume 11 Issue 25 of @Oncotarget reported that this study aimed to define the mutation profile of SUM in Caucasians.
Next-generation sequencing-based genomic analysis was used to identify frequently mutated loci in 50 cancer-related genes in 31 SUM primary tumors.
The most abundant mutations in SUM were found in KIT – in 13% of cases and NRAS – also in 13%, while BRAF - only in 3% of cases.
The authors' findings confirmed a high frequency of KIT and NRAS mutations in SUM, as well as a low incidence of BRAF mutations.
They reported novel KRAS, CTNNB1, TP53, ERBB2, and SMAD4 mutations in SUM.
Dr. Aneta Borkowska from The Mari...2020-06-2303 min
OncotargetOncotarget - Mutation Profile Of Primary Subungual Melanomas In CaucasiansVolume 11 Issue 25 of @Oncotarget reported that this study aimed to define the mutation profile of SUM in Caucasians.
Next-generation sequencing-based genomic analysis was used to identify frequently mutated loci in 50 cancer-related genes in 31 SUM primary tumors.
The most abundant mutations in SUM were found in KIT – in 13% of cases and NRAS – also in 13%, while BRAF - only in 3% of cases.
The authors' findings confirmed a high frequency of KIT and NRAS mutations in SUM, as well as a low incidence of BRAF mutations.
They reported novel KRAS, CTNNB1, TP53, ERBB2, and SMAD4 mutations in SUM.
Dr. Aneta Borkowska from The Mari...2020-06-2303 min
OncotargetOncotarget - RSK Inhibitor BI - D1870 Inhibits Acute Myeloid Leukemia Cell ProlferationVolume 11, Issue 25 of @Oncotarget reported that to examine the role of RSK in AML, the authors analyzed apoptosis and the cell cycle profile following treatment with BI-D1870, a potent inhibitor of RSK. BI-D1870 treatment increased the G2/M population and induced apoptosis in Acute Myeloid Leukemia cell lines and patient Acute Myeloid Leukemia cells.
Therefore, the authors investigated whether BI-D1870 potentiates the anti-leukemic activity of vincristine by targeting mitotic exit.
Combination treatment of BI-D1870 and vincristine synergistically increased mitotic arrest and apoptosis in acute leukemia cells.
These data show that BI-D1870 induces apoptosis of AML cells alone and in combination...2020-06-2304 min
OncotargetOncotarget: Second Line Trastuzumab Emtansine Following Horizongal Dual BlockadeVolume 11, Issue 22 of Oncotarget reported that despite relevant medical advancements, metastatic breast cancer remains an incurable disease.
HER2 signaling conditions tumor behavior and treatment strategies of HER2 expressing breast cancer.
Cancer treatment guidelines uniformly identify dual blockade with pertuzumab and trastuzumab plus a taxane as best first line and trastuzumab emtansine as a preferred second-line choice.
However, there is no prospectively designed available study focusing on the sequence and outcomes of patients treated with T-DM1 following the triplet.
In the following report, data concerning a wide series of patients treated in a real-life setting are presented.
Results obtained in terms...2020-06-0303 min
OncotargetOncotarget: Anticancer Effect Of Physical Activity Is MediatedVolume 11, Issue 22 of Oncotarget reported that the goal of this study was to explore the involvement of mi RNAs in beneficial effects exerted by physical activity in breast cancer prevention.
The levels of extracellular mi RNAs were evaluated in blood plasma before and after structured exercise by means of microarray analysis of 1,900 mi RNAs identifying mostly modulated mi RNAs. The different expressions of two mi RNAs involved in breast cancer progression, i. e. up-regulation of mi R-206 and down-regulation of anti-miR-30c, were the most striking effects induced by exercise.
The biological effects of these mi RNAs were investigated in...2020-06-0303 min
OncotargetOncotarget: Anticancer Effect Of Physical Activity Is MediatedVolume 11, Issue 22 of Oncotarget reported that the goal of this study was to explore the involvement of mi RNAs in beneficial effects exerted by physical activity in breast cancer prevention.
The levels of extracellular mi RNAs were evaluated in blood plasma before and after structured exercise by means of microarray analysis of 1,900 mi RNAs identifying mostly modulated mi RNAs. The different expressions of two mi RNAs involved in breast cancer progression, i. e. up-regulation of mi R-206 and down-regulation of anti-miR-30c, were the most striking effects induced by exercise.
The biological effects of these mi RNAs were investigated in...2020-06-0303 min
OncotargetOncotarget Interview with Dr. Arieh Eden from the Lady Davis Carmel Medical Center in Haifa, IsraelThe cover for issue 6 of Oncotarget features Figure 3, "The effect of NCs treatments on routine lab results during disease and recovery progress," by Ben-Nun-Shaul, et al.
Numerous previous attempts to develop therapeutic treatments, directed at discreet targets of the sepsis cascade, could not cope with the complex pathophysiology of sepsis and failed.
Studies in a severe rat sepsis model showed that pre-treatment by NCs led to a dramatic increase in survival, from zero to 75%.
Further studies are needed to determine whether when applied after sepsis onset, the NCs still improve outcomes.
Dr. Arieh Eden from the Department of Anesthesiology, Critical...2020-02-1209 min
OncotargetOncotarget Interview with Dr. Arieh Eden from the Lady Davis Carmel Medical Center in Haifa, IsraelThe cover for issue 6 of Oncotarget features Figure 3, "The effect of NCs treatments on routine lab results during disease and recovery progress," by Ben-Nun-Shaul, et al.
Numerous previous attempts to develop therapeutic treatments, directed at discreet targets of the sepsis cascade, could not cope with the complex pathophysiology of sepsis and failed.
Studies in a severe rat sepsis model showed that pre-treatment by NCs led to a dramatic increase in survival, from zero to 75%.
Further studies are needed to determine whether when applied after sepsis onset, the NCs still improve outcomes.
Dr. Arieh Eden from the Department of Anesthesiology, Critical...2020-02-1209 min
OncotargetDr. Beatrice Aramini from the University of Modena and Reggio Emilia in Modena Italy | OncotargetOncotarget interviews Dr. Beatrice Aramini from the University of Modena and Reggio Emilia in Modena Italy about their Featured Cover Paper for Volume 11 Issue 5 titled "Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study"
PRESS RELEASE: The cover for issue 5 of Oncotarget features Figure 2, "Survival curves in the KRAS, EGFR, and niche mutations cohorts," by Aramini, et al.
Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET.
The multivariable analysis showed that:
Niche mutations had higher mortality than EGFR mutations
KRAS mutations had higher mortality than EGFR mutations, and
Niche mutations pres...2020-02-0406 min
OncotargetDr. Beatrice Aramini from the University of Modena and Reggio Emilia in Modena Italy | OncotargetOncotarget interviews Dr. Beatrice Aramini from the University of Modena and Reggio Emilia in Modena Italy about their Featured Cover Paper for Volume 11 Issue 5 titled "Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study"
PRESS RELEASE: The cover for issue 5 of Oncotarget features Figure 2, "Survival curves in the KRAS, EGFR, and niche mutations cohorts," by Aramini, et al.
Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET.
The multivariable analysis showed that:
Niche mutations had higher mortality than EGFR mutations
KRAS mutations had higher mortality than EGFR mutations, and
Niche mutations pres...2020-02-0406 min